Recent Updates — ABBV
AbbVie Inc. reported third-quarter 2026 financial results, posting GAAP diluted earnings per share of $2.37 and adjusted diluted EPS of $3.82. Net revenues reached $17.4 billion, a 10.5 percent increase on an operational basis, driven by strong growth in the immunology portfolio where Skyrizi generated $5.78 billion. The company raised its full-year 2026 adjusted diluted EPS guidance range to $13.95-$13.99 from $13.76-$13.96 and announced a 5.2 percent increase in its quarterly dividend to $1.82 per share, payable February 16, 2027. AbbVie is a pharmaceutical company focused on immunology, neuroscience, oncology, and aesthetics.
On October 14, 2026, AbbVie Inc. expanded its Board of Directors from twelve to thirteen members and appointed Dr. John M. Carethers as a Class II director. Dr. Carethers currently serves as the Vice Chancellor for Health Sciences at the University of California San Diego and was previously a director of Avantor, Inc. He has been appointed to the Public Policy and Sustainability Committee and is classified as an independent director under NYSE standards. AbbVie operates in the pharmaceutical industry, developing and commercializing innovative medicines.
AbbVie Inc. updated its financial outlook for 2026, lowering the full-year adjusted diluted earnings per share range to $13.76–$13.96 from a previous high of $14.07. The revision reflects an estimated $216 million in pre-tax acquired in-process research and development (IPR&D) and milestone expenses incurred during the third quarter, which reduced both GAAP and adjusted diluted EPS by $0.11 per share. Consequently, the company also lowered its third-quarter 2026 adjusted diluted EPS guidance to a range of $3.73–$3.77. AbbVie Inc. operates as a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies.
AbbVie completed its acquisition of Apogee Therapeutics on September 3, 2026. Under the agreement, Apogee shareholders received $135.11 per share in cash for a total equity value of approximately $10.9 billion. The transaction adds late-stage assets zumilokibart (APG777) and APG273 to AbbVie's immunology pipeline targeting atopic dermatitis, asthma, and COPD. AbbVie expects the acquisition to dilute adjusted diluted EPS by $0.14 in 2026 and approximately $0.46 in 2027, with accretion beginning in 2032. The company reaffirmed its full-year 2026 adjusted diluted EPS guidance of $13.87 to $14.07 and third-quarter guidance of $3.84 to $3.88. AbbVie is a pharmaceutical company focused on immunology, neuroscience, oncology, and aesthetics.
On August 18, 2026, AbbVie Inc. completed a $9.5 billion underwritten public offering of senior notes to fund its acquisition of Apogee Therapeutics, Inc. The issuance included $500 million in floating rate notes due 2028, $1 billion in 4.500% notes due 2028, $1.25 billion in 4.650% notes due 2030, $1.5 billion in 4.875% notes due 2031, $1.25 billion in 5.050% notes due 2033, $1.5 billion in 5.300% notes due 2036, $1 billion in 5.450% notes due 2038, $1.5 billion in 6.000% notes due 2056, and $500 million in 6.100% notes due 2066. Proceeds will primarily cover cash consideration for the Apogee acquisition and related expenses, with remaining funds allocated to general corporate purposes. The company operates in the biopharmaceutical industry.
On August 4, 2026, AbbVie Inc. entered into an underwriting agreement to issue and sell $9.5 billion in aggregate principal amount of senior notes across multiple maturities ranging from 2028 to 2066. The offering includes floating rate notes due 2028, fixed-rate notes due 2028, 2030, 2031, 2033, 2036, 2038, 2056, and 2066. Net proceeds are expected to be approximately $9.93 billion after deducting underwriting discounts and offering expenses. AbbVie intends to use these funds to finance a portion of its cash payment obligations for the acquisition of Apogee Therapeutics, Inc., pay related fees and expenses, and reduce commitments under its $10.0 billion 364-day delayed draw term loan facility associated with that transaction. The closing is expected on August 18, 2026. AbbVie operates in the pharmaceutical industry, developing and commercializing innovative medicines.